# ImmCelz (CELZ-100) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/celz-100

> The FDA approved ImmCelz (CELZ-100), sponsored by CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ), on Mar 2024 for brittle Type 1 Diabetes.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ImmCelz (CELZ-100) |
| Codes | CELZ-100 |
| Sponsor | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) https://sec-api.dev/companies/celz/catalysts |
| Indications | brittle type 1 diabetes |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Mar 2024: FDA approval

- Status: completed, approved. Date confidence: month. Indication: Brittle Type 1 Diabetes.
- First seen 2026-06-25, last confirmed 2026-06-25.
- SEC registration statement (S-1) (accession 0001477932-26-004010): "In March 2024, the FDA approved our application for Orphan Drug Designation ("ODD") with respect to our ImmCelz™ (CELZ-100) platform for the treatment of Brittle Type 1 Diabetes." https://www.sec.gov/Archives/edgar/data/1187953/000147793226004010/celz_s1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/celz-100.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ImmCelz (CELZ-100) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/celz-100

```bibtex
@misc{secapidev_pdufa_celz_100_20261116,
  title        = {ImmCelz (CELZ-100) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/celz-100}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_celz_100_20261116","title":"ImmCelz (CELZ-100) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/celz-100","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
